Herpes zoster (shingles) vaccine (recombinant, adjuvanted)

Concepts

• vaccines
• herpes zoster
• supply of herpes zoster
• provision of a vaccine
• vaccine
• shingles
• recombinant
• legitimate commercial interest of the supplier
• national immunisation programme
• years

Location

United Kingdom:

Description

Contract for the supply of herpes zoster, inactivated vaccine

Total Quantity or Scope

The provision of a vaccine to protect against Shingles, to be used in the national immunisation programme. Deliveries will be required over the initial term of 3 years and the contract has the option to be extended for up to an additional 12 months. Additional information: Value - The value has been withheld so as not to prejudice the legitimate commercial interest of the supplier

Award Detail

Renewal Options

This contract has the option to be extended for up to an additional 12 months

Award Criteria

CPV Codes

• 33651600 - Vaccines

Indicators

• Options are available.

Legal Justification

The Contracting Authority used the negotiated procedure without prior publication under Regulation 32(2)(b)(iii) – to protect exclusive rights - to purchase a quantity of Shingrix. The JCVI has made a recommendation that Shingrix exclusively be used for the national shingles vaccination programme due to the superiority of the vaccine and DHSC is obliged by law to adopt that recommendation, and the Supplier has global exclusive legal rights to manufacture and distribute Shingrix.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** The contract(s) is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract(s) may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes.